Business
Sensus Healthcare Reports Record Sales and Earnings for the 2021 Fourth Quarter
4Q21 diluted EPS of $0.32 on revenues of $13.0 million up 433% and 156%, respectively Affirms expectations for 1Q22 continued growth and full-year 2022
About this update from Sensus Healthcare, Inc.
[{"type":"text","content":"4Q21 diluted EPS of $0.32 on revenues of $13.0 million up 433% and 156%, respectively Affirms expectations for 1Q22 continued growth and full-year 2022 profitability Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive, and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and 12 months ended December 31, 2021. Highlights from the fourth quarter of 2021 and recent weeks include the following (all comparisons are with the fourth quarter of 2020, unless otherwise indicated): Revenues were $13.0 million, up 156%Net income was $5.3 million, or $0.32 per diluted share, compared with net income of $1.0 million, or $0.06 per diluted shareAdjusted EBITDA, a non-GAAP financial measure, was $5.6 million, compared with $1.3 millionShipped a record 35 systems including three SRT-100 systems to ChinaRevenues for 2021 were $27.0 million, up 182% over 2020Earnings per diluted share for 2021 were $0.25, compared with a loss per share of $0.42 for 2020Affirms expectations for 2022 first quarter and full year profitabilitySigned exclusive U.S. distribution agreement for TransDermal Infusion System™ for needle-less delivery of aesthetic compoundsPrepared for future growth with key promotions, including Vice President & General Counsel Michael J. Sardano to President & General CounselReceived a five-year license renewal for the SRT-100™ from the Ministry of Health of the People’s Republic of ChinaGarnered robust customer leads from demonstrations and presentations at first in-person medical conferences since the start of the pandemic Management Commentary “Record revenues for the fourth quarter were significantly higher than for any quarter in the company’s history, and I congratulate the Sensus team on outstanding Q4 and full-year financial results,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. “We are comfortable that this momentum will continue through 2022 as so many of our initiatives are being very well-executed. “We shipped a record 35 systems during the fourth quarter, including three systems to China, where we resumed active sales this year following the pandem...